BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 24606459)

  • 1. Effect of TLR4 and B7-H1 on immune escape of urothelial bladder cancer and its clinical significance.
    Wang YH; Cao YW; Yang XC; Niu HT; Sun LJ; Wang XS; Liu J
    Asian Pac J Cancer Prev; 2014; 15(3):1321-6. PubMed ID: 24606459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TLR4 signaling induces B7-H1 expression through MAPK pathways in bladder cancer cells.
    Qian Y; Deng J; Geng L; Xie H; Jiang G; Zhou L; Wang Y; Yin S; Feng X; Liu J; Ye Z; Zheng S
    Cancer Invest; 2008 Oct; 26(8):816-21. PubMed ID: 18608206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
    Sweis RF; Galsky MD
    Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of TLR4-induced IL-6 response in bladder cancer cells by opposing actions of MAPK and PI3K signaling.
    Qian Y; Deng J; Xie H; Geng L; Zhou L; Wang Y; Yin S; Feng X; Zheng S
    J Cancer Res Clin Oncol; 2009 Mar; 135(3):379-86. PubMed ID: 18825409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors.
    Berthon C; Driss V; Liu J; Kuranda K; Leleu X; Jouy N; Hetuin D; Quesnel B
    Cancer Immunol Immunother; 2010 Dec; 59(12):1839-49. PubMed ID: 20814675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells.
    Barsoum IB; Smallwood CA; Siemens DR; Graham CH
    Cancer Res; 2014 Feb; 74(3):665-74. PubMed ID: 24336068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-12 regulates B7-H1 expression in ovarian cancer-associated macrophages by effects on NF-κB signalling.
    Xiong HY; Ma TT; Wu BT; Lin Y; Tu ZG
    Asian Pac J Cancer Prev; 2014; 15(14):5767-72. PubMed ID: 25081699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Costimulatory molecule B7-H1 on the immune escape of bladder cancer and its clinical significance.
    Wang Y; Zhuang Q; Zhou S; Hu Z; Lan R
    J Huazhong Univ Sci Technolog Med Sci; 2009 Feb; 29(1):77-9. PubMed ID: 19224168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model.
    Okudaira K; Hokari R; Tsuzuki Y; Okada Y; Komoto S; Watanabe C; Kurihara C; Kawaguchi A; Nagao S; Azuma M; Yagita H; Miura S
    Int J Oncol; 2009 Oct; 35(4):741-9. PubMed ID: 19724910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
    Zhou TC; Sankin AI; Porcelli SA; Perlin DS; Schoenberg MP; Zang X
    Urol Oncol; 2017 Jan; 35(1):14-20. PubMed ID: 27816403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers.
    Nakanishi J; Wada Y; Matsumoto K; Azuma M; Kikuchi K; Ueda S
    Cancer Immunol Immunother; 2007 Aug; 56(8):1173-82. PubMed ID: 17186290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor Escape Phenotype in Bladder Cancer Is Associated with Loss of HLA Class I Expression, T-Cell Exclusion and Stromal Changes.
    Gil-Julio H; Perea F; Rodriguez-Nicolas A; Cozar JM; González-Ramirez AR; Concha A; Garrido F; Aptsiauri N; Ruiz-Cabello F
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway.
    Liu J; Hamrouni A; Wolowiec D; Coiteux V; Kuliczkowski K; Hetuin D; Saudemont A; Quesnel B
    Blood; 2007 Jul; 110(1):296-304. PubMed ID: 17363736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-1 and PD-L1 are more highly expressed in high-grade bladder cancer than in low-grade cases: PD-L1 might function as a mediator of stage progression in bladder cancer.
    Kawahara T; Ishiguro Y; Ohtake S; Kato I; Ito Y; Ito H; Makiyama K; Kondo K; Miyoshi Y; Yumura Y; Hayashi N; Hasumi H; Osaka K; Muraoka K; Izumi K; Teranishi JI; Uemura H; Yao M; Nakaigawa N
    BMC Urol; 2018 Nov; 18(1):97. PubMed ID: 30400941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder.
    Xylinas E; Robinson BD; Kluth LA; Volkmer BG; Hautmann R; Küfer R; Zerbib M; Kwon E; Thompson RH; Boorjian SA; Shariat SF
    Eur J Surg Oncol; 2014 Jan; 40(1):121-7. PubMed ID: 24140000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer-associated Fibroblast-derived Extracellular Vesicles Mediate Immune Escape of Bladder Cancer via PD-L1/PD-1 Expression.
    Feng R; Li Z; Ge G; Wang C; Jia Y; Ouyang J
    Endocr Metab Immune Disord Drug Targets; 2023; 23(11):1410-1420. PubMed ID: 36852791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival.
    Boorjian SA; Sheinin Y; Crispen PL; Farmer SA; Lohse CM; Kuntz SM; Leibovich BC; Kwon ED; Frank I
    Clin Cancer Res; 2008 Aug; 14(15):4800-8. PubMed ID: 18676751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between messenger RNA expression and protein expression of immune checkpoint-associated molecules in bladder urothelial carcinoma: A retrospective study.
    Le Goux C; Damotte D; Vacher S; Sibony M; Delongchamps NB; Schnitzler A; Terris B; Zerbib M; Bieche I; Pignot G
    Urol Oncol; 2017 May; 35(5):257-263. PubMed ID: 28291636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Morphine-3-glucuronide upregulates PD-L1 expression
    Wang K; Wang J; Liu T; Yu W; Dong N; Zhang C; Xia W; Wei F; Yang L; Ren X
    Cancer Biol Med; 2021 Feb; 18(1):155-171. PubMed ID: 33628591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myeloma Drug Resistance Induced by Binding of Myeloma B7-H1 (PD-L1) to PD-1.
    Ishibashi M; Tamura H; Sunakawa M; Kondo-Onodera A; Okuyama N; Hamada Y; Moriya K; Choi I; Tamada K; Inokuchi K
    Cancer Immunol Res; 2016 Sep; 4(9):779-88. PubMed ID: 27440711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.